New Delhi [India], June 14: The Fondazione Ricerca e Innovazione Cardiovascolare (RIC) has successfully finished patient enrolment for TRANSFORM II, one of the most ambitious and extensive randomised controlled trials (RCTs) ever carried out in the field of cardiovascular care, at a pivotal point for the future of interventional cardiology. In order to treat de-novo coronary artery disease, this international project is contrasting the popular everolimus-eluting stent (EES) with the innovative MagicTouch Sirolimus-Coated Balloon (SCB).
Source link








